New hope for PAH patients: IKT-001 enters final trial phase
NCT ID NCT07365332
First seen Feb 02, 2026 · Last updated May 01, 2026 · Updated 10 times
Summary
This study tests a new drug called IKT-001 for people with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs makes it hard to breathe and move. About 486 adults aged 18 to 75 will receive either the drug or a placebo to see if it improves blood flow and walking distance. The goal is to control the disease and ease symptoms, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.